On July 15, Giant Biogene rose 5.28% in regular trading, trading at HK$28.26/share, with turnover of approximately HK$72.71 million.
On the news front, the company's medical aesthetics product matrix has been landing at an accelerated pace. In June, its subsidiary's 753 collagen injection — China's first recombinant Type I collagen facial injectable — officially launched, while a cross-linked recombinant Type III full-length collagen filler received NMPA approval as the world's first such product indicated for neck wrinkle correction.
Huachuang Securities noted in a research report that Giant Biogene's medical aesthetics matrix has gradually taken shape, with cosmetics-related public opinion risks nearing a clearing inflection point. CICC maintains an Outperform rating with a target price of HK$40, while Oriental Securities maintains a Buy rating with a target price of HK$43.07, both citing improving fundamentals and the company's expanding full-category coverage spanning Class III medical devices, Class II devices, and skincare products.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments